Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -211.7% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 5.4 | n/a |
Pr/Book | 5.1 |
Latest | F'cast | |
---|---|---|
Revenue | 10.5% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 1.70 | (3.51) | (17.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 1.16 | (6.95) | (27.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 2.40 | (10.54) | (32.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 4.57 | (8.90) | (0.28)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | 5.05 | (10.62) | (0.31)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Positive FDA Feedback on Phase 2 Study Design | 04-Sep-2025 | 07:00 | RNS |
Holding(s) in Company | 28-Aug-2025 | 12:00 | RNS |
Change of Auditor | 08-Aug-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 72.50p |
Change Today | 2.00p |
% Change | 2.84 % |
52 Week High | 80.00 |
52 Week Low | 38.00 |
Volume | 79,597 |
Shares Issued | 37.76m |
Market Cap | £27.37m |
Beta | 0.00 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
15:25 | 20,093 @ 74.63p |
14:40 | 1,608 @ 74.63p |
14:12 | 4,227 @ 74.63p |
13:05 | 1,000 @ 74.25p |
11:58 | 673 @ 74.25p |
You are here: research